Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease

Abstract

Currently, no reliable predictors of cognitive impairment in Parkinson's disease exist. We hypothesized that microstructural changes at grey matter T1-weighted MRI and diffusion tensor imaging in the cholinergic system nuclei and associated limbic pathways underlie cognitive impairment in Parkinson's disease. We performed a cross-sectional comparison between patients with Parkinson's disease with and without cognitive impairment. We also performed a longitudinal 36-month follow-up study of cognitively intact Parkinson's disease patients, comparing patients who remained cognitively intact to those who developed cognitive impairment. Patients with Parkinson's disease with cognitive impairment showed lower grey matter volume and increased mean diffusivity in the nucleus basalis of Meynert, compared to patients with Parkinson's disease without cognitive impairment. These results were confirmed both with region of interest and voxel-based analyses, and after partial volume correction. Lower grey matter volume and increased mean diffusivity in the nucleus basalis of Meynert was predictive for developing cognitive impairment in cognitively intact patients with Parkinson's disease, independent of other clinical and non-clinical markers of the disease. Structural and microstructural alterations in entorhinal cortex, amygdala, hippocampus, insula, and thalamus were not predictive for developing cognitive impairment in Parkinson's disease. Our findings provide evidence that degeneration of the nucleus basalis of Meynert precedes and predicts the onset of cognitive impairment, and might be used in a clinical setting as a reliable biomarker to stratify patients at higher risk of cognitive decline.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 48

1. 1.

   Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol2003; 60: 387–92.

   Not in our library10.1001/archneur.60.3.387

2. 2.

   Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci reports2012; 12: 492–501.

   Not in our library10.1007/s11910-012-0290-7

3. 3.

   Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Cognitive decline in Parkinson disease. Nat Rev Neurol2017; 13: 217–31.

   Not in our library10.1038/nrneurol.2017.27

4. 4.

   Anang JB, Nomura T, Romenets SR, Nakashima K, Gagnon JF, Postuma RB Dementia predictors in Parkinson disease: a validation study. J Parkinsons Dis2017; 7: 159–62.

   Not in our library10.3233/jpd-160925

5. 5.

   Andersson JL, Skare S, Ashburner J How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage2003; 20: 870–88.

   Not in our library10.1016/s1053-8119(03)00336-7

6. 6.
   An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging · 2016

   No notice
7. 7.

   Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci2003; 6: 750–7.

   Not in our library10.1038/nn1075

8. 8.

   Bohnen NI, Albin RL The cholinergic system and Parkinson disease. Behav Brain Res2011a; 221: 564–73.

   Not in our library10.1016/j.bbr.2009.12.048

9. 9.

   Bohnen NI, Albin RL White matter lesions in Parkinson disease. Nat Rev Neurol2011b; 7: 229–36.

   Not in our library10.1038/nrneurol.2011.21

10. 10.

    Bohnen NI, Bogan CW, Muller ML Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections. Eur Neurol J2009a; 1: 33–50.

    Not in our library

11. 11.

    Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol2003; 60: 1745–8.

    Not in our library10.1001/archneur.60.12.1745

12. 12.

    Bohnen NI, Muller ML, Kuwabara H, Constantine GM, Studenski SA Age-associated leukoaraiosis and cortical cholinergic deafferentation. Neurology2009b; 72: 1411–6.

    Not in our library10.1212/wnl.0b013e3181a187c6

13. 13.

    Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol2006; 112: 389–404.

    Not in our library10.1007/s00401-006-0127-z

14. 14.

    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging2003; 24: 197–211.

    Not in our library10.1016/s0197-4580(02)00065-9

15. 15.

    Burciu RG, Ofori E, Archer DB, Wu SS, Pasternak O, McFarland NR, Progression marker of Parkinson's disease: a 4-year multi-site imaging study. Brain2017; 140: 2183–92.

    Not in our library10.1093/brain/awx146

16. 16.

    Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain2004; 127 (Pt 4): 791–800.

    Not in our library10.1093/brain/awh088

17. 17.

    Chen FX, Kang DZ, Chen FY, Liu Y, Wu G, Li X, Gray matter atrophy associated with mild cognitive impairment in Parkinson's disease. Neurosci Lett2016; 617: 160–5.

    Not in our library10.1016/j.neulet.2015.12.055

18. 18.

    Choi HJ, Zilles K, Mohlberg H, Schleicher A, Fink GR, Armstrong E, Cytoarchitectonic identification and probabilistic mapping of two distinct areas within the anterior ventral bank of the human intraparietal sulcus. J Compar Neurol2006; 495: 53–69.

    Not in our library10.1002/cne.20849

19. 19.

    Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage2005; 25: 1325–35.

    Not in our library10.1016/j.neuroimage.2004.12.034

20. 20.

    Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron2002; 33: 341–55.

    Not in our library10.1016/s0896-6273(02)00569-x

21. 21.

    Fischl B, Salat DH, van der Kouwe AJ, Makris N, Segonne F, Quinn BT, Sequence-independent segmentation of magnetic resonance images. Neuroimage2004; 23 (Suppl 1): S69–84.

    Not in our library10.1016/j.neuroimage.2004.07.016

22. 22.

    Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology2010; 75: 1270–6.

    Not in our library10.1212/wnl.0b013e3181f61311

23. 23.

    Gratwicke J, Jahanshahi M, Foltynie T Parkinson's disease dementia: a neural networks perspective. Brain2015; 138 (Pt 6): 1454–76.

    Not in our library10.1093/brain/awv104

24. 24.

    Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp2012; 33: 727–39.

    Not in our library10.1002/hbm.21245

25. 25.

    Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord2008; 23: 837–44.

    Not in our library10.1002/mds.21956

26. 26.
    Effects of acetylcholine on neuronal properties in entorhinal cortex · 2012

    Not checked
27. 27.

    Kurth F, Eickhoff SB, Schleicher A, Hoemke L, Zilles K, Amunts K Cytoarchitecture and probabilistic maps of the human posterior insular cortex. Cereb Cortex2010; 20: 1448–61.

    Not in our library10.1093/cercor/bhp208

28. 28.

    Lee JE, Cho KH, Song SK, Kim HJ, Lee HS, Sohn YH, Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry2014; 85: 7–16.

    Not in our library10.1136/jnnp-2013-305062

29. 29.

    Leritz EC, Shepel J, Williams VJ, Lipsitz LA, McGlinchey RE, Milberg WP, Associations between T1 white matter lesion volume and regional white matter microstructure in aging. Hum Brain Mapp2014; 35: 1085–100.

    Not in our library10.1002/hbm.22236

30. 30.

    Ma J, Jiang Q, Xu J, Sun Q, Qiao Y, Chen W, Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease. Dement Geriatr Cogn disorders2015; 39: 251–6.

    Not in our library10.1159/000371510

31. 31.

    Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry2012; 83: 188–94.

    Not in our library10.1136/jnnp-2011-300828

32. 32.

    Mesulam MM, Mufson EJ, Levey AI, Wainer BH Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Compar Neurol1983; 214: 170–97.

    Not in our library10.1002/cne.902140206

33. 33.

    Moore SF, Barker RA Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease. Parkinsonism Relat Disord2014; 20 (Suppl 1): S104–7.

    Not in our library10.1016/s1353-8020(13)70026-9

34. 34.

    Muller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, beta-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord2013; 28: 296–301.

    Not in our library10.1002/mds.25213

35. 35.

    Parkinson J An essay on the shaking palsy: London: Whittingham and Rowland for Sherwood, Neely and Jones; 1817.

    Not in our library

36. 36.

    Rogers JD, Brogan D, Mirra SS The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol1985; 17: 163–70.

    Not in our library10.1002/ana.410170210

37. 37.
    Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts · 2017

    No notice
38. 38.

    Salat DH, Tuch DS, van der Kouwe AJ, Greve DN, Pappu V, Lee SY, White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging2010; 31: 244–56.

    Not in our library10.1016/j.neurobiolaging.2008.03.013

39. 39.
    Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology · 2016

    No notice
40. 40.

    Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol2017; 16: 66–75.

    Not in our library10.1016/s1474-4422(16)30328-3

Cited by papers we hold 2

• Inconsistencies in atlas-based volumetric measures of the human nucleus basalis of Meynert: A need for high-resolution alternatives · 2022
  Not checked
• Combined subthalamic and nucleus basalis of Meynert deep brain stimulation for Parkinson’s disease with dementia (DEMPARK-DBS): protocol of a randomized, sham-controlled trial · 2020
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.